Open an account

Alterity Therapeutics

ATHE · ASX

$2.09−$0.06 (−2.79%)TodayMarket closed ·
Prev close $2.15

About ATHE

Alterity Therapeutics Ltd. is a clinical stage biotechnology company. The company is headquartered in Melbourne, Victoria and currently employs 9 full-time employees. The company went IPO on 2000-03-28. The firm is focused on developing disease modifying treatments for neurodegenerative diseases. The firm's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. The company has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The firm also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. Its lead asset, ATH434, is in a randomized, double blind, placebo-controlled Phase II clinical trial in participants with MSA. The firm is also conducting various nonclinical studies with ATH434 for use in Parkinson’s disease based on imaging of brain iron, preservation of neurons, and improvements in motor performance.

Employees
9
Headquarters
Melbourne, Victoria
Listed
Mar 28, 2000
Sector
Health Care
Industry
Biotechnology
Website
alteritytherapeutics.com

ATHE key statistics

Market cap
60.72M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
31.50K
Volume
26.79K
Open price
$2.12
High today
$2.43
Low today
$2.04
52 Week high
$5.89
52 Week low
$2.09

Alterity Therapeutics (ATHE) at a glance

As of Oct 23, 2026, Alterity Therapeutics (ATHE) shares are priced at $2.09, giving the company a market cap of 60.72M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $2.04 and $2.43. The current price is 2.5% above the day's low and 14.0% below its high.

Volume so far is 26.79K shares, in line with the average of 31.50K shares a day.

Over the past year Alterity Therapeutics has ranged from $2.09 to $5.89, and now sits 0% of the way up that range.

The average analyst price target is $8.74, 318.1% above the current price, from 5 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 5 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $8.74
Low
$8.65
Now
$2.09
High
$9.00

ATHE news

  • Vandana Singh

    Alterity Therapeutics Secures Key US Patent for Lead Asset

  • Vandana Singh

    Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular Disorder

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's Intraday Session

  • Avi Kapoor

    Nasdaq Moves Lower; Meta Platforms Posts Strong Sales

  • Avi Kapoor

    Dow Jumps Over 100 Points; Tesla Earnings Miss Views

  • Press releaseGlobe Newswire

    Appendix 4C – Q2 FY25 Quarterly Cash Flow Report

Similar companies

Companies in the same industry as Alterity Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.